Table 3 Recent major and pivotal clinical trials for targeted therapy in PDAC
From: Molecular alterations and targeted therapy in pancreatic ductal adenocarcinoma
Agent | Therapeutic mechanism | Target | Study phase | Numbers of patients (with PDAC) | Efficacy | Clinical trial | Reference |
|---|---|---|---|---|---|---|---|
Erlotinib | Tyrosine kinase inhibition | EGFR | Phase III | 436 | DFS and OS not improved | CONKO-005 | DRKS00000247 |
Phase III | 449 | OS not improved | LAP07 | NCT00634725 | |||
Vandetanib | EGFR, RET, VEGFR2 | Phase II | 142 | OS not improved | Â | EudraCT2007-004299-38, ISRCTN96297434 | |
Nimotuzumab | Monoclonal antibody | EGFR | Phase IIb | 186 | Longer OS in KRASWT, HR = 0.69 | Â | EudraCT2007-000338-38, OSAG101-PCS07, NCT00561990 |
MK-0646 | IGF-1R | Phase II | 75 | OS improved | Â | NCT00769483 | |
MCLA-128 (Zenocutuzumab) | ERBB3 | Phase II | recruiting | Â | Â | NCT02912949 | |
Selumetinib and MK-2206 | Oncogenic pathway inhibition | PI3K and MEK | Phase II | 137 | PFS and OS not improved | SWOG S1115 | NCT01658943 |
Olaparib | Synthetic lethality | PARP | Phase III | 164 | Longer PFS, HR = 0.53 | POLO trial | NCT02184195 |
Pembrolizumab | Immune checkpoint blockade | PD-1 | Phase Ib | 24 | ORR = 0 | KEYNOTE-028 | NCT02054806 |
Phase II | 22 | ORR = 18.2 | KEYNOTE-158 | NCT02628067 | |||
CAR T | Target tumour-associated antigens | HER2 | Phase I | 2 | SD = 2 | Â | NCT01935843 |
Mesothelin | Phase I | 5 | SD = 3, PD = 2 | Â | NCT02159716 | ||
CD133 | Phase I | 7 | PR = 2, SD = 3, PD = 2 | Â | NCT02541370 |